patents.google.com

PT1036783E - CRYSTALLINE HYDRATE CALCIUM SALT OF SIMVASTATIN IN THE FORM OF OPEN DIHYDROXYACIDES - Google Patents

  • ️Fri Aug 29 2003
CRYSTALLINE HYDRATE CALCIUM SALT OF SIMVASTATIN IN THE FORM OF OPEN DIHYDROXYACIDES

Info

Publication number
PT1036783E
PT1036783E PT00301864T PT00301864T PT1036783E PT 1036783 E PT1036783 E PT 1036783E PT 00301864 T PT00301864 T PT 00301864T PT 00301864 T PT00301864 T PT 00301864T PT 1036783 E PT1036783 E PT 1036783E Authority
PT
Portugal
Prior art keywords
dihydroxyacides
simvastatin
open
calcium salt
crystalline hydrate
Prior art date
1999-03-08
Application number
PT00301864T
Other languages
Portuguese (pt)
Inventor
Edward J J Grabowski
Paul J Reider
Richard D Tillyer
Feng Xu
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
1999-03-08
Filing date
2000-03-07
Publication date
2003-08-29
2000-03-07 Application filed by Merck & Co Inc filed Critical Merck & Co Inc
2003-08-29 Publication of PT1036783E publication Critical patent/PT1036783E/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/22—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety
    • C07C69/30—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety esterified with trihydroxylic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/26—All rings being cycloaliphatic the ring system containing ten carbon atoms
    • C07C2602/28—Hydrogenated naphthalenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
PT00301864T 1999-03-08 2000-03-07 CRYSTALLINE HYDRATE CALCIUM SALT OF SIMVASTATIN IN THE FORM OF OPEN DIHYDROXYACIDES PT1036783E (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12324799P 1999-03-08 1999-03-08
US26474599A 1999-03-09 1999-03-09
PCT/US2000/002627 WO2000053566A1 (en) 1999-03-08 2000-02-02 Crystalline hydrated dihydroxy open-acid simvastatin calcium salt

Publications (1)

Publication Number Publication Date
PT1036783E true PT1036783E (en) 2003-08-29

Family

ID=26821372

Family Applications (1)

Application Number Title Priority Date Filing Date
PT00301864T PT1036783E (en) 1999-03-08 2000-03-07 CRYSTALLINE HYDRATE CALCIUM SALT OF SIMVASTATIN IN THE FORM OF OPEN DIHYDROXYACIDES

Country Status (16)

Country Link
EP (2) EP1163203A1 (en)
JP (2) JP2002539108A (en)
AR (1) AR022857A1 (en)
AT (1) ATE240934T1 (en)
AU (1) AU764048B2 (en)
CA (1) CA2365869A1 (en)
CO (1) CO5150184A1 (en)
DE (1) DE60002769T9 (en)
DK (1) DK1036783T3 (en)
ES (1) ES2198253T3 (en)
HN (1) HN2000000031A (en)
PE (1) PE20001469A1 (en)
PT (1) PT1036783E (en)
SI (1) SI1036783T1 (en)
SV (1) SV2002000035A (en)
WO (1) WO2000053566A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6558659B2 (en) 2000-04-10 2003-05-06 Teva Pharmaceutical Industries Ltd. Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids
USRE44578E1 (en) 2000-04-10 2013-11-05 Teva Pharmaceutical Industries, Ltd. Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids
CA2421018A1 (en) * 2000-09-06 2002-03-14 Merck & Co., Inc. Dihydroxy open-acid salt of simvastatin
CA2422820A1 (en) * 2000-09-19 2002-03-28 Novimmune S.A. Use of statins (hmg-coa reductase inhibitors) for the preparation of medicament as a novel type of immunomodulator, immunosuppressor and anti-inflammatory agent
US6777552B2 (en) 2001-08-16 2004-08-17 Teva Pharmaceutical Industries, Ltd. Processes for preparing calcium salt forms of statins
WO2002057229A1 (en) 2001-01-19 2002-07-25 Biocon India Limited FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)
ES2338530T3 (en) 2002-03-18 2010-05-10 Biocon Limited HMG-COA INHIBITORS REDUCE AMORPHES OF THE DESIRED PARTICLE SIZE.
US20030195167A1 (en) * 2002-04-15 2003-10-16 Kowa Co., Ltd. PTX3-gene expression inhibitor
AU2003276960A1 (en) * 2002-06-13 2003-12-31 Novartis Ag Calcium salts of indole derived statins
AR040588A1 (en) 2002-07-26 2005-04-13 Schering Corp PHARMACEUTICAL FORMULATION INCLUDING AN INHIBITOR OF CHOLESTEROL ABSORPTION AND AN INHIBITOR OF A HMGCO TO REDUCTASE
US6995277B2 (en) 2003-02-11 2006-02-07 Plus Chemicals, B.V. Process for preparing simvastatin having controlled ranges of simvastatin dimer content
US7368581B2 (en) 2003-06-18 2008-05-06 Teva Pharmaceutical Industries Ltd. Process for the preparation of fluvastatin sodium crystal from XIV
US7368468B2 (en) 2003-06-18 2008-05-06 Teva Pharmaceutical Industries Ltd. Fluvastatin sodium crystal forms XIV, LXXIII, LXXIX, LXXX and LXXXVII, processes for preparing them, compositions containing them and methods of using them
KR20060024428A (en) 2003-06-18 2006-03-16 테바 파마슈티컬 인더스트리즈 리미티드 Fluvastatin sodium crystal form, preparation method thereof, composition comprising the crystal form and method using the crystal form
US7816405B2 (en) 2005-04-19 2010-10-19 Eisai R&D Management Co., Ltd. Calcium bis [(2S)-3-[3-[(2S)-3-(4-chloro-2-cyanophenoxy)-2-fluoropropoxy]phenyl ]-2-isopropoxypropionate] and intermediate thereof
AU2006240821A1 (en) * 2005-04-19 2006-11-02 Eisai R & D Management Co., Ltd. Calcium bis[(2S)-3-[3-[(2S)-3-(4-chloro-2-cyanophenoxy)-2- fluoropropoxy]phenyl]-2-isopropoxypropionate] and intermediate thereof
JP2013537724A (en) * 2010-08-27 2013-10-03 アドバンスド テクノロジー マテリアルズ，インコーポレイテッド How to prevent high aspect ratio structural collapse during drying
US20150202313A1 (en) * 2012-08-31 2015-07-23 New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery Macromolecular Prodrugs for Hard Tissue and Methods of Use Thereof
GB201704687D0 (en) 2017-03-24 2017-05-10 Wockhardt Uk Ltd Pharmaceutical composition of simvastatin or salt thereof
CN113686991A (en) * 2021-08-31 2021-11-23 南京西默思博检测技术有限公司 Method for determining simvastatin and beta-hydroxy acid simvastatin in human plasma

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444784A (en) * 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
FI94339C (en) * 1989-07-21 1995-08-25 Warner Lambert Co Process for the preparation of pharmaceutically acceptable [R- (R *, R *)] - 2- (4-fluorophenyl) -, - dihydroxy-5- (1-methylethyl) -3-phenyl-4 - [(phenylamino) carbonyl] -1H- for the preparation of pyrrole-1-heptanoic acid and its pharmaceutically acceptable salts
US5223415A (en) * 1990-10-15 1993-06-29 Merck & Co., Inc. Biosynthetic production of 7-[1',2',6',7',8',8a'(R)-hexahydro-2'(S),6'(R)-dimethyl-8'(S)-hydroxy-1'(S)-naphthyl]-3(R),5(R)-dihydroxyheptanoic acid (triol acid)

Also Published As

Publication number Publication date
SV2002000035A (en) 2002-01-15
HN2000000031A (en) 2001-09-25
DK1036783T3 (en) 2003-06-23
PE20001469A1 (en) 2000-12-18
AR022857A1 (en) 2002-09-04
EP1036783B1 (en) 2003-05-21
AU2637000A (en) 2000-09-28
EP1163203A1 (en) 2001-12-19
JP2000281626A (en) 2000-10-10
SI1036783T1 (en) 2003-08-31
AU764048B2 (en) 2003-08-07
ES2198253T3 (en) 2004-02-01
CA2365869A1 (en) 2000-09-14
CO5150184A1 (en) 2002-04-29
EP1036783A1 (en) 2000-09-20
ATE240934T1 (en) 2003-06-15
DE60002769D1 (en) 2003-06-26
JP2002539108A (en) 2002-11-19
DE60002769T9 (en) 2004-11-04
DE60002769T2 (en) 2004-03-18
WO2000053566A1 (en) 2000-09-14

Similar Documents

Publication Publication Date Title
PT1036783E (en) 2003-08-29 CRYSTALLINE HYDRATE CALCIUM SALT OF SIMVASTATIN IN THE FORM OF OPEN DIHYDROXYACIDES
HUS1900052I1 (en) 2020-01-28 2-acylaminothiazole derivative or salt thereof
DK1313714T3 (en) 2008-12-15 Valsartan salts
PT1296947E (en) 2004-05-31 PERINDOPRIL TERC.-BUTILAMINE ALPHA CRYSTALLINE FORM
SG109439A1 (en) 2005-03-30 Sulfonium salt compounds
DE60021299D1 (en) 2005-08-25 Economy of a transport refrigeration unit
NO20014817L (en) 2001-11-28 Water dispenser with filter integrity system
ZA200500621B (en) 2006-07-26 2-cyano-4-fluoropyrrolidine derivative or its salt
PL346731A1 (en) 2001-10-08 Derivatives of diazepane or their salts
ATE236899T1 (en) 2003-04-15 NEW CRYSTALLINE FORM OF THE POTASSIUM SALT OF (S)-OMEPRAZOLE
PT1445249E (en) 2013-01-16 Novel bensophenone derivatives or salts thereof
HUP0202536A3 (en) 2003-04-28 Crystals of the sodium salt of pravastatin
DE60040922D1 (en) 2009-01-08 CONTAINER CLOSURE
NO20020030D0 (en) 2002-01-04 Crystalline 1-methylcarbapenem compounds
DE50108797D1 (en) 2006-04-13 CLOSURE LID
PT1233960E (en) 2003-11-28 POLYMERIC SALT
EP1623972A4 (en) 2007-07-25 Solid n-acylalanine or salts thereof
DE50109001D1 (en) 2006-04-27 CLOSURE LID
IS6007A (en) 2001-07-17 New morpholinobenzamide salts
DE69903567D1 (en) 2002-11-21 ELECTRO-DIP COATINGS CONTAINING CALCIUM SALTS
ATA127299A (en) 2000-09-15 KIT FOR THE FORMATION OF A WATER ODOR CLOSURE
HK1059535A1 (en) 2004-07-09 Antimicrobial locks comprising taurinamide derivatives and carboxylic acids and/or salts thereof
ATA117199A (en) 2001-06-15 DRINKING WATER STORAGE
AU2000230000A1 (en) 2001-08-27 Disposable water resistant foamed concrete cover for bulk salt
ATA12752000A (en) 2002-12-15 CONTAINER CLOSURE